GI
CRNX icon

GAMMA Investing’s Crinetics Pharmaceuticals CRNX Stock Holding History

GAMMA Investing’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3K Buy
436
+34
+8% +$1.26K ﹤0.01% 2952
2026
Q1 		$14.6K Sell
402
-58
-13% -$2.59K ﹤0.01% 2879
2025
Q4 		$21.4K Buy
460
+227
+97% +$10.1K ﹤0.01% 2573
2025
Q3 		$9.7K Sell
233
-111
-32% -$3.55K ﹤0.01% 2889
2025
Q2 		$9.89K Buy
344
+142
+70% +$4.38K ﹤0.01% 2813
2025
Q1 		$6.78K Buy
202
+96
+91% +$3.58K ﹤0.01% 2940
2024
Q4 		$5.42K Sell
106
-12
-10% -$671 ﹤0.01% 2885
2024
Q3 		$6.03K Buy
118
+53
+82% +$2.73K ﹤0.01% 2679
2024
Q2 		$2.91K Buy
65
+7
+12% +$323 ﹤0.01% 2761
2024
Q1 		$2.71K Buy
58
+16
+38% +$626 ﹤0.01% 2650
2023
Q4 		$1.53K Buy
+42
New +$1.29K ﹤0.01% 2662

Other funds holding CRNX

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
LAM
Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
PAS
Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

GAMMA Investing's CRNX Position: Q2 2026 in Review

GAMMA Investing increased its Crinetics Pharmaceuticals (CRNX) stake by 8.5% in Q2 2026, buying an estimated $1.26K and bringing the position to 436 shares worth $16.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2952.

GAMMA Investing first reported a position in CRNX in Q4 2023 and has held it in 11 quarters since. The position peaked at $21.4K in Q4 2025. 21 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • GAMMA Investing held 436 shares of Crinetics Pharmaceuticals worth $16.3K as of Q2 2026.
  • GAMMA Investing bought 34 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.26K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2952 holding.
  • GAMMA Investing first reported a position in Crinetics Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • GAMMA Investing's Crinetics Pharmaceuticals position peaked at $21.4K in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.